Company Focus
Merck KGaA
Latest Merck KGaA News
Pharmaceutical
Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). 13 June 2025
Related News
Insights
Company Spotlight
A clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease.
Latest News & Features of interest to Merck KGaA
Pharmaceutical
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA). 30 June 2025
Biotechnology
US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells through RNA delivery using tLNPs, for up to $2.1 billion in cash. 30 June 2025
Biotechnology
US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. 30 June 2025
Pharmaceutical
US biopharma Alto Neuroscience, a firm focused on the development of novel precision medicines for neuropsychiatric disorders, has highlighted The Lancet Psychiatry’s publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). 30 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has announced the elimination of the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor CAR-T cell immunotherapies. 30 June 2025
Pharmaceutical
US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide reduced weight by 20%. In deal-making news last week, US drugmaker Amarin struck a deal with Italy’s Recordati for the marketing of its cardiovascular drug Vazkepa in 59 countries, mostly Europe. Also, USA-based Vor Bio signed an exclusive agreement to acquire to RemeGen’s myasthenia drug telitacicept. Also of note, the US Centers for Disease Control and Prevention CDC) new advisory committee, the ACIP, met last week to review a number of vaccines. 29 June 2025
Biotechnology
Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell for investigational therapies aimed at interleukin-11 (IL-11), including a Phase I-stage monoclonal antibody targeting age-related conditions. 27 June 2025
Pharmaceutical
German drugmaker Bayer has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D. 27 June 2025
Biotechnology
In a significant showcase for investors, BeOne Medicines announced major advancements to its industry-leading oncology pipeline during an investor R&D Day. 27 June 2025
Biotechnology
Italian drugmaker Philogen has announced its decision to voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy(daromun), a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. 27 June 2025
Latest In Brief for Merck KGaA
Biotechnology
The benefits from Eli Lilly’s Kisluna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute for Health and Care Excellence (NICE), which also rejected Japanese drugmaker Eisai and US biotech Biogen Leqembi (lecanemab) for the same reason. 19 June 2025
Latest Relevant Ones To Watch News
US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells through RNA delivery using tLNPs, for up to $2.1 billion in cash. 30 June 2025
17 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze